COMMERCIAL FEATURE

THE NEW REGENERATION

Hydrinity COO, Brent Nixon, shares his insights on the difference between the aesthetic markets in the UK and US and the future of longevity in aesthetics

WHAT ARE THE KEY OPERATIONAL AND CLINICAL DIFFERENCES YOU’VE OBSERVED BETWEEN THE US AND UK AESTHETIC MARKETS?

“In the UK, there seems to be a higher proportion of cosmetic doctors compared to the US, where practitioners are often more strictly divided between medical dermatologists and plastic surgeons due to private and insurance-driven healthcare. “This makes UK doctors very open-minded, but also more conservative. They are slightly more critical of new technology. However, the UK is a proving ground; European markets look to it for leadership.

“The UK generally follows US trends, but at a slower, more cautious pace. There is healthy scepticism here towards heavily marketed products. But when practitioners see solid clinical science, they come on board quickly.”

GIVEN HOW CROWDED THE PROFESSIONAL SKINCARE MARKET IS, WHY LAUNCH A NEW RANGE IN THE UK NOW?

“A lot of traditional professional brands in the UK have gone directly to consumers online or into retail. Practitioners are losing their point of difference. Hydrinity is strictly direct to clinic.

“Aesthetic patients want instant gratification, and clinicians want to achieve the best possible outcomes as fast as possible.

“What sets us apart is speed and clinical rigour. Skincare is often hype-based or influencer-driven. We come from a regenerative medicine and oncology background. In our third-party clinical trials, including a 71-patient study, we demonstrated measurable results in parameters like luminosity, elasticity, and pore reduction in as little as two weeks, compared to the standard eight -week timeline.”

HOW ARE PATIENT EXPECTATIONS AROUND DOWNTIME AND POST-PROCEDURE RECOVERY EVOLVING?

“Patients are moving away from the old philosophy that you have to break the skin down and suffer through severe redness, peeling, or a 10-step daily regimen to get results.

“We advocate for ‘Skinimalism,’ which is maximising the power of individual products so that one formula replaces three or four.

“Recovery is also becoming as critical as the treatment itself. Reducing downtime minimises complications, alleviates patient anxiety, and increases retention. If a patient recovers in three days rather than ten, they are much more likely to return for subsequent treatments. In a 24-patient study, our restorative technology accelerated epithelial recovery by 280% within 24 hours, effectively cutting post-procedure downtime in half.”

WHAT MISTAKES ARE PRACTITIONERS MAKING WHEN IT COMES TO RETAIL AND HOW CAN THEY OVERCOME THEM?

“The biggest mistake is that practitioners try to sell rather than prescribe. There is an anxiety around retail sales. But when a patient comes to a clinic, they are seeking a medical outcome. If a child has an earache, a doctor doesn’t ask if you’d like to buy amoxicillin; they prescribe it. Practitioners need to treat postprocedure skincare as essential medicine required to deliver the promised result.

“It’s about managing the entire treatment journey. Clinics must guide the patient through pre-conditioning and post-care. If a patient is not willing to invest in protecting their skin investment, they aren’t going to get the best clinical outcome.”

REGENERATIVE AESTHETICS IS A MAJOR BUZZWORD TODAY. HOW DO YOU CUT THROUGH THE MARKETING NOISE?

“Regenerative is often used as a marketing term, but true regeneration requires getting active ingredients down into the dermis where cellular repair occurs. Most topical HA molecules are too large and sit on the surface. Our parent company spent nearly a decade developing an injectable-grade, micro-HA molecule that is 10 to 15 times smaller than standard hyaluronic acid, allowing it to penetrate deep into the dermis to stimulate fibroblast proliferation and collagen synthesis.”

LOOKING AHEAD, WHAT DO YOU BELIEVE WILL DEFINE THE NEXT PHASE OF AESTHETIC MEDICINE?

“Longevity through evidence-based medicine. The industry is moving away from short-lived, trendy treatments that get dropped after two years due to poor outcomes or negativity. Practitioners are looking for brands built on clinical proof.

“The future belongs to true technological innovation rather than just reskinning ingredients. Whether it’s targeted delivery systems or novel biomimetic exosomes, peer-reviewed clinical rigor is raising the bar. That focus on science is what keeps professional skincare in the hands of medical experts rather than online algorithms.”